subscribeSubscribe
price-trendAsk Us
Glenmark introduces medication to prevent chemotherapy-induced nausea

Glenmark introduces medication to prevent chemotherapy-induced nausea
ECONOMIC TIMES
23 Jan 2023
Share Share
FDA Confirms Paragraph IV Patent Litigation for Aprepitant, Azilsartan, Bupivacaine, Cladribine, Elrombopag, Fosnetupitant, Fostamatinib, Ivacaftor and Sodium Thiosulfate.

FDA Confirms Paragraph IV Patent Litigation for Aprepitant, Azilsartan, Bupivacaine, Cladribine, Elrombopag, Fosnetupitant, Fostamatinib, Ivacaftor and Sodium Thiosulfate.
FDA
13 Jun 2022
Share Share
FDA Confirms Paragraph IV Patent Litigation for Fosnetupitant Chloride Hydrochloride and Palonosetron Hydrochloride

FDA Confirms Paragraph IV Patent Litigation for Fosnetupitant Chloride Hydrochloride and Palonosetron Hydrochloride
FDA
13 Jun 2022
Share Share
Taiho Pharmaceutical Submits New Drug Application for NK1 Receptor

Taiho Pharmaceutical Submits New Drug Application for NK1 Receptor
PRESS RELEASE
23 Mar 2021
Share Share
Helsinn Group announces AKYNZEO® injection – a new liquid IV solution

Helsinn Group announces AKYNZEO® injection – a new liquid IV solution
GLOBENEWSWIRE
20 Aug 2020
Share Share
Helsinn announces launch of oral formulation of Akynzeo® in China

Helsinn announces launch of oral formulation of Akynzeo® in China
GLOBENEWSWIRE
08 Jun 2020
Share Share
Five meds recommended in final 2019 CHMP meeting

Five meds recommended in final 2019 CHMP meeting
Anna Smith PHARMA TIMES
16 Dec 2019
Share Share
Glenmark launches Helsinn`s Akynzeo in India

Glenmark launches Helsinn`s Akynzeo in India
BIOSPECTRUM
11 Jul 2018
Share Share
Glenmark expands its oncology franchise in India with launch of Akynzeo

Glenmark expands its oncology franchise in India with launch of Akynzeo
ECONOMIC TIMES
11 Jul 2018
Share Share